Kevin Patrick Moran - Mar 4, 2024 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Signature
/s/ Kevin Patrick Moran
Stock symbol
VNDA
Transactions as of
Mar 4, 2024
Transactions value $
-$63,393
Form type
4
Date filed
3/6/2024, 04:46 PM
Previous filing
Feb 21, 2024
Next filing
Jul 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Sale -$26K -5.8K -2.36% $4.48 240K Mar 4, 2024 Direct F1, F2
transaction VNDA Common Stock Sale -$37.4K -8.9K -3.71% $4.20 231K Mar 5, 2024 Direct F1, F3
holding VNDA Common Stock 635 Mar 4, 2024 By Wife
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.